Table 3.

Laboratory values at baseline, weeks 4 and 8, and end of study (ITT population)a

ParameterBaseline (Mean ± SD)End of Week 4 (Mean ± SD)End of Week 8 (Mean ± SD)End of Study or LOCF (Mean ± SD)
Predialysis serum phosphorus (mg/dl)6.97 ± 1.78 (n = 435)5.56 ± 1.60 (n = 383)b5.45 ± 1.40 (n = 297)b5.96 ± 1.85 (n = 413)b
Corrected serum calcium (mg/dl)9.38 ± 0.73 (n = 431)9.56 ± 0.69 (n = 370)b9.58 ± 0.71 (n = 285)b9.53 ± 0.79 (n = 404)b
Ca × P (mg2/dl2)66.0 ± 17.5 (n = 352)53.3 ± 14.6 (n = 339)b51.8 ± 13.3 (n = 254)b56.8 ± 16.8 (n = 336)b
Biointact PTH (pg/ml)266 ± 192 (n = 422)248 ± 179 (n = 383)c271 ± 197 (n = 296)287 ± 239 (n = 410)d
Serum albumin (g/dl)3.68 ± 0.331 (n = 506)e3.66 ± 0.36 (n = 383)3.68 ± 0.34 (n = 295)3.64 ± 0.366 (n = 424)c
  • a Ca × P, calcium-phosphorus product; ITT, intention-to-treat; LOCF, last observation carried forward; PTH, parathyroid hormone.

  • b P ≤ 0.0001 for the comparison with baseline.

  • c P < 0.05 for the comparison with screening.

  • d P = 0.0042 for the comparison with baseline.

  • e Serum albumin levels at screening.\